Stifel Nicolaus analyst Rick Wise reiterated a Hold rating on Obalon Therapeutics Inc (NASDAQ: OBLN) yesterday and set a price target of $2. The company’s shares closed yesterday at $1.66, close to its 52-week low of $1.46.
According to TipRanks.com, Wise is a 5-star analyst with an average return of 15.7% and a 73.8% success rate. Wise covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Intuitive Surgical, and Becton Dickinson.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Obalon Therapeutics Inc with a $3.17 average price target, representing a 91.0% upside. In a report released yesterday, Northland Securities also upgraded the stock to Hold.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.40 and a one-year low of $1.46. Currently, Obalon Therapeutics Inc has an average volume of 118.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Obalon Therapeutics, Inc. focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Its product includes medical balloon technology for weight loss therapy which consists of a capsule containing a balloon that is swallowed and then remotely inflated.
